Cardiovascular diseases are known as one of major causes of morbidity and mortality
worldwide. Despite the many advancement in therapies are associated with cardiovascular …

Cardiovascular disease remains the leading cause of death worldwide. Acute ischaemic
injury and chronic cardiomyopathies lead to permanent loss of cardiac tissue and ultimately …

Background—Phase I clinical studies have demonstrated the feasibility of implanting
autologous skeletal myoblasts in postinfarction scars. However, they have failed to …

Objectives: This study evaluated the use of an injectable hydrogel derived from ventricular
extracellular matrix (ECM) for treating myocardial infarction (MI) and its ability to be delivered …

Cellular cardiomyoplasty is an attractive option for the treatment of severe heart failure. It is,
however, still unclear and controversial which is the most promising cell source. Therefore …

Tissue engineering may provide an alternative to cell injection as a therapeutic solution for
myocardial infarction. A tissue-engineered muscle patch may offer better host integration …

Background—Therapeutic efficacy of bone marrow (BM) cell injection for treating ischemic
chronic heart failure has not been established. In addition, experimental data are lacking on …

Aims Although mesenchymal stem cells (MSCs) show promising signs in reducing
myocardial infarct (MI) size, the safety of endomyocardial delivery and the most efficacious …

So far, the major safety issue raised by the use of stem cells for cardiac repair has been the
occurrence of ventricular arrhythmias, particularly after skeletal myoblast transplantation …

Background To improve the efficacy of bone marrow-derived mesenchymal stem cell (MSC)
therapy targeted to infarcted myocardium, we investigated whether a self-setting silanized …